Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Yufeng Wang China

一家源于China的处于临床阶段的生物技术公司，聚焦于研发自身免疫疾病领域的创新药，为China和全世界患者提供未满足的临床用药。

Website:
www.reistonebio.com
Company Size (Fulltime employees)
51-200
Partnering Objectives
Please specify your partnering goal
License in/out
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Yufeng Wang
Reistone Biopharma
Senior Director BD 

Mei Wang China

biotech focusing on world leading r&d to solve unmet medical needs
Website:
www.dizalpharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
dizal pharmaceutical
team leader 

Yuqi Wang China

QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
Website:
www.parkinsons-disease-care.mysxl.cn
Partnering Objectives
Headquartner in China
Yes
QiRun Biotech
Founder 

Cynthia Wang China

.
Website:
www.Servier.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Assets based licensing in
Headquartner in China
No
Servier
BD&Licensing Director 

Ms. Danni Wang China

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
Website:
www.harbourbiomed.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Licensing-out and Licensing-in of targeted therapeutic areas
Headquartner in China
Yes
Harbour BioMed
Senior Director, Business Development 
Functionality
Business Development

grace wang China

DENTAL MATERIALS
STENTS
EPIDEMIC PREVENTION PRODUCTS ETC.
Website:
www.atmbio.com
Partnering Objectives
Headquartner in China
Yes
Beijing ATMbiomaterials Co., Ltd
MD 

Dr Yinxiang Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Chairman and CEO 
Functionality
Management

William Wang China

see company website
Website:
www.tiandapharma.com
Partnering Objectives
Headquartner in China
Yes
Tianda Pharmaceutical Ltd.
CEO 

Mr. Jibo Wang China

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs
Website:
https://www.luye.cn
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
more RA knowledge
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Luye pharma
RA specialist 

Dr. Weiqing Wang China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
AnHeart Therapeutics
Associate Director of BD 
Functionality
Business Development